Clinical Trial Results:
Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and paranasal cavity and in patients with acute rhinitis – SeptaNazal DOUBLE clinical study.
Summary
|
|
EudraCT number |
2015-005155-27 |
Trial protocol |
SI HR |
Global end of trial date |
06 Mar 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2020
|
First version publication date |
04 Jun 2020
|
Other versions |
|
Summary report(s) |
Final Report Synopsis |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
KCT09/2015-SeptaNazal-Double
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Krka d.d., Novo mesto
|
||
Sponsor organisation address |
Dunajska cesta 65, Ljubljana, Slovenia, 1000
|
||
Public contact |
Tanja Kohek, Krka d.d., Novo mesto
Dunajska cesta 65
1000 Ljubljana
Slovenia, 00386 41589769, tanja.kohek@krka.biz
|
||
Scientific contact |
Tanja Kohek, Krka d.d., Novo mesto
Dunajska cesta 65
1000 Ljubljana
Slovenia, 00386 41589769, tanja.kohek@krka.biz
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
31 Jul 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
06 Mar 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Mar 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of the double blind, randomized trial is to compare the efficacy of the treatment between fixed combination of xylometazoline and dexpanthenol (Septanazal®), nasal spray, and xylometazoline, nasal spray, on nasal congestion and the healing effect of dexpanthenol in patients with acute rhinitis and in patients after surgery in the nose and paranasal cavity.
|
||
Protection of trial subjects |
Patients were not included in the clinical study if they were hypersensitive to the active substances or to any of the excipients, if they had dry nasal inflammation, if they received local or systemic flu treatment, sympathomimetics or if they concomitantly received another nasal decongestant.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 Jan 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Slovenia: 17
|
||
Country: Number of subjects enrolled |
Croatia: 177
|
||
Worldwide total number of subjects |
194
|
||
EEA total number of subjects |
194
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
194
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||
Recruitment details |
There were 154 patients with acute rhinitis (Group 1) and 40 patients after an operation in the nose and paranasal cavities (Group 2) enrolled in the study. | |||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||
Screening details |
In general, patients aged 18-60 years, with nasal occlusion after an operation in the nose and paranasal cavities or with acute rhinitis, were eligible for inclusion in the study. Eligible patients needed to tolerate intranasal administration of the IMP and sign informed consent form (ICF). | |||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||
Arm title
|
Acute Rhinitis + Xylometazoline | |||||||||||||||||||||||||
Arm description |
Patients with acute Rhinitis who were treated only with Xylometazoline. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
Nasal spray with Xylometazoline
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Nasal spray, solution
|
|||||||||||||||||||||||||
Routes of administration |
Nasal use
|
|||||||||||||||||||||||||
Dosage and administration details |
Nasal spray with 0.1% Xylometazoline 3 times per day 1 spray in each nostril.
|
|||||||||||||||||||||||||
Arm title
|
Acute Rhinitis + Xylometazoline + Dexpanthenol | |||||||||||||||||||||||||
Arm description |
Patients with acute Rhinitis who were treated with Xylometazoline and Dexpanthenol. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
Nasal spray with Xylometazoline and Dexpanthenol
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Nasal spray, solution
|
|||||||||||||||||||||||||
Routes of administration |
Nasal use
|
|||||||||||||||||||||||||
Dosage and administration details |
Nasal spray with 0.1% Xylometazoline and 5% Dexpanthenol 3 times per day 1 spray in each nostril.
|
|||||||||||||||||||||||||
Arm title
|
Nose operation + Xylometazoline | |||||||||||||||||||||||||
Arm description |
Patients after an operation in the nose and paranasal cavities who were treated only with Xylometazoline. There were 40 patients altogether after an operation in the nose and paranasal cavities. 23 were treated only with Xylometazoline and 17 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
Nasal spray with Xylometazoline
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Nasal spray, solution
|
|||||||||||||||||||||||||
Routes of administration |
Nasal use
|
|||||||||||||||||||||||||
Dosage and administration details |
Nasal spray with 0.1% Xylometazoline 3 times per day 1 spray in each nostril.
|
|||||||||||||||||||||||||
Arm title
|
Nose operation + Xylometazoline + Dexpanthenol | |||||||||||||||||||||||||
Arm description |
Patients after an operation in the nose and paranasal cavities who were treated with Xylometazoline and Dexpanthenol. There were 40 patients altogether after an operation in the nose and paranasal cavities. 23 were treated only with Xylometazoline and 17 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
Nasal spray with Xylometazoline and Dexpanthenol
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Nasal spray, solution
|
|||||||||||||||||||||||||
Routes of administration |
Nasal use
|
|||||||||||||||||||||||||
Dosage and administration details |
Nasal spray with 0.1% Xylometazoline and 5% Dexpanthenol 3 times per day 1 spray in each nostril.
|
|||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Acute Rhinitis + Xylometazoline
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with acute Rhinitis who were treated only with Xylometazoline. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Acute Rhinitis + Xylometazoline + Dexpanthenol
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with acute Rhinitis who were treated with Xylometazoline and Dexpanthenol. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nose operation + Xylometazoline
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients after an operation in the nose and paranasal cavities who were treated only with Xylometazoline. There were 40 patients altogether after an operation in the nose and paranasal cavities. 23 were treated only with Xylometazoline and 17 were treated with Xylometazoline and Dexpanthenol. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nose operation + Xylometazoline + Dexpanthenol
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients after an operation in the nose and paranasal cavities who were treated with Xylometazoline and Dexpanthenol. There were 40 patients altogether after an operation in the nose and paranasal cavities. 23 were treated only with Xylometazoline and 17 were treated with Xylometazoline and Dexpanthenol. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Acute Rhinitis + Xylometazoline
|
||
Reporting group description |
Patients with acute Rhinitis who were treated only with Xylometazoline. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | ||
Reporting group title |
Acute Rhinitis + Xylometazoline + Dexpanthenol
|
||
Reporting group description |
Patients with acute Rhinitis who were treated with Xylometazoline and Dexpanthenol. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | ||
Reporting group title |
Nose operation + Xylometazoline
|
||
Reporting group description |
Patients after an operation in the nose and paranasal cavities who were treated only with Xylometazoline. There were 40 patients altogether after an operation in the nose and paranasal cavities. 23 were treated only with Xylometazoline and 17 were treated with Xylometazoline and Dexpanthenol. | ||
Reporting group title |
Nose operation + Xylometazoline + Dexpanthenol
|
||
Reporting group description |
Patients after an operation in the nose and paranasal cavities who were treated with Xylometazoline and Dexpanthenol. There were 40 patients altogether after an operation in the nose and paranasal cavities. 23 were treated only with Xylometazoline and 17 were treated with Xylometazoline and Dexpanthenol. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Investigator`s assessment of nasal patency using anterior Rhinoscopy | ||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The primary objective was to compare the efficacy of nasal sprays of a fixed combination of xylometazoline and dexpanthenol (Septanazal®) and xylometazoline in the nasal congestion of patients with acute rhinitis and patients after operation in the nose and paranasal cavities.
The researcher examined the right and left nasal cavities of all patients using anterior rhinoscopy and evaluated the degree of global patency in the nasal cavity determined by the VAS (Visual Analogue Scale) scale (0 - complete nasal patency, 10 - completely occluded nose). The examination was performed on Visit 1 (Day 1), Visit 2 (Day 3) and Visit 3 (Day 7).
In all patients (treated with either Septanazal or xylometazoline), the patency in both nasal cavities improved during treatment, which is directly indicated by a decrease in nasal obstruction from the first to the last visit.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days for one patient and was the same for the whole duration of the study.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Nasal patency across visits | ||||||||||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
The efficacy of Septanazal and xylomethazoline in the reduction of nasal occlusion was compared between visits using asymptotic z-test. Both Septanazal and xylomethazoline expressed statistically significant reduction in nasal occlusion between visits 1 and 2, 2 and 3 as well as 1 and 3.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
Acute Rhinitis + Xylometazoline v Acute Rhinitis + Xylometazoline + Dexpanthenol v Nose operation + Xylometazoline v Nose operation + Xylometazoline + Dexpanthenol
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Method |
asymptotic z-test | ||||||||||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Patient`s assessment of nasal patency | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
The primary objective was to compare the efficacy of nasal sprays of a fixed combination of xylometazoline and dexpanthenol (Septanazal®) and xylometazoline in the nasal congestion of patients with acute rhinitis and patients after operation in the nose and paranasal cavities.
The patient also evaluated nasal patency using a VAS scale. Nasal patency was assessed before IMP administration and 1 minute, 3 minutes, 6 minutes and 9 minutes after IMP administration.
Both Septanazal and xylometazoline effect was observed within 1 minute of administration. Even greater is the reduction of nasal occlusion after 3, 6 and 9 minutes after application of any IMP.
There were no statistically significant differences between Septanazal and xylometazoline before and 1 minute, 3 minutes, 6 minutes and 9 minutes after IMP administration.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days for one patient and was the same for the whole duration of the study.
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Comparing efficacy of nasal sprays | |||||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
The efficacy of Septanazal and xylomethazoline in the reduction of nasal occlusion was compared with the statistical comparison of means of VAS reductions in patients treated with Septanazal and patients treated with xylomethazoline, using either the unpaired t-test or the Wilcoxon-Mann-Whitney test, if the assumptions for unpaired t-test were not met.
|
|||||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
Acute Rhinitis + Xylometazoline v Acute Rhinitis + Xylometazoline + Dexpanthenol v Nose operation + Xylometazoline v Nose operation + Xylometazoline + Dexpanthenol
|
|||||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
194
|
|||||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||||||||||||||||||||
Analysis type |
other [1] | |||||||||||||||||||||||||||||||||||||||||||||
P-value |
< 0.05 | |||||||||||||||||||||||||||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - In patients with acute Rhinitis (Group 1) all differences between Septanazal and xylomethazoline efficacy were statistically insignificant (before IMP P=0.28185, 1 min P=0.55145, 3 min P=0.29645, 6 min P=0.15029, 9 min P=0.17259). In patients with after nose surgery (Group 2) all differences between Septanazal and xylomethazoline efficacy were statistically insignificant (before IMP P=0.70127, 1 min P=0.88677, 3 min P=0.50163, 6 min P=0.36600, 9 min P=0.24734). |
|
|||||||||||||||||||||||||||||||
End point title |
Questionnaire SNOT-22 REV 2 - "Nose occlusion" | ||||||||||||||||||||||||||||||
End point description |
SNOT-22 REV 2 is a questionnaire used to evaluate acute inflammation of the nasal mucosa and chronic inflammation of the nasal mucosa and the paranasal cavities. Of the 22 questions asked, one was about "nose occlusion". The question was evaluated with points from 0 to 5, with the number representing the severity of the symptoms (0 - symptom no problem, 5 - symptom most severe).
PATIENTS AFTER NOSE SURGERY: A statistically significant comparison of the average values of nasal occlusion was found at the 3rd visit, in favor of Septanazal and was 1.0, p=0.020. Comparison of differences in reduction of nasal occlusion from V1 to V3 between the two studied groups was statistically insignificant.
PATIENTS WITH ACUTE RHINITIS: Average values of nasal occlusion on 1st and 3rd visit as well as comparison of differences in reduction of nasal occlusion from V1 to V3 between the two studied groups were statistically insignificant.
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
7 days for one patient and was the same for the whole duration of the study.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Statistical analysis title |
SNOT-22 REV 2 - Nose occlusion | ||||||||||||||||||||||||||||||
Comparison groups |
Acute Rhinitis + Xylometazoline v Acute Rhinitis + Xylometazoline + Dexpanthenol v Nose operation + Xylometazoline v Nose operation + Xylometazoline + Dexpanthenol
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||||||||||||
Confidence interval |
|
||||||||||||||||||||||||||||||||||||
End point title |
Patient`s subjective assessment of obstructed breathing | |||||||||||||||||||||||||||||||||||
End point description |
After the IMP application, the patient evaluated the severity of 11 symptoms on a scale from 0 to 4 (0 - symptom no problems, 4 - symptom very serious problems). One of the symptoms was the "sensation of obstructed breathing through the nose", which directly indicates nasal occlusion. The evaluation took place at all three visits.
PATIENTS AFTER NOSE SURGERY: The observed symptom decreased statistically significantly from the V1 to the V3 (decrease by 41% in the xylometazoline group (p = 0.031) and 49% in the Septanazal group (p = 0.004)).
PATIENTS WITH ACUTE RHINITIS: The observed symptom decreased statistically significantly from the V1 to the V3 (a decrease of 63% in the xylometazoline group (p <0.0001) and 64% in the Septanazal group (p <0.0001)).
|
|||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||
End point timeframe |
7 days for one patient and was the same for the whole duration of the study.
|
|||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Patient`s subjective assessment | |||||||||||||||||||||||||||||||||||
Comparison groups |
Acute Rhinitis + Xylometazoline v Acute Rhinitis + Xylometazoline + Dexpanthenol v Nose operation + Xylometazoline v Nose operation + Xylometazoline + Dexpanthenol
|
|||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
194
|
|||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||||||||||||||||
P-value |
< 0.05 | |||||||||||||||||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||
End point title |
Global assessment of individual`s behavior - GAIB | ||||||||||||||||||||||||||||||
End point description |
At V2 and V3, the investigator evaluated the improvement in signs and symptoms during treatment using GAIB. GAIB contains a 7-point rating (0 - fully improved, 6 - worse disease/condition than at baseline). GAIB compared the end state versus the severity of the initial condition.
PATIENTS AFTER NOSE SURGERY: The mean score decreased from V2 to V3 for 0.38 (35%, P=0.0078) in the group treated with Septanazal and for 0.39 (25%, P=0.0019) in the group treated with xylometazoline. Comparison of mean global estimates of improvement did not show a statistically significant difference between the groups studied.
PATIENTS WITH ACUTE RHINITIS: The mean score decreased from V2 to V3 for 0.96 (52%, P<0.0001) in the group treated with Septanazal and for 0.72 (47%, P<0.0001) in the group treated with xylometazoline. Comparison of mean global estimates of improvement showed a statistically significant difference between the groups only on V2 with Septanazal group having a higher score (p<0.027).
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
7 days for one patient and was the same for the whole duration of the study.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Statistical analysis title |
Global assessment of individual`s behavior | ||||||||||||||||||||||||||||||
Comparison groups |
Acute Rhinitis + Xylometazoline v Acute Rhinitis + Xylometazoline + Dexpanthenol v Nose operation + Xylometazoline v Nose operation + Xylometazoline + Dexpanthenol
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
192
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||||||||||||
Confidence interval |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Timeframe for AE reporting for one patient was 7 days and was the same for the whole duration of the study (from the day the first patient entered (23.1.2017) to the day the last patient concluded the study (6.3.2018)).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Acute Rhinitis + Xylometazoline
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with acute Rhinitis who were treated only with Xylometazoline. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Acute Rhinitis + Xylometazoline + Dexpanthenol
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with acute Rhinitis who were treated with Xylometazoline and Dexpanthenol. There were 154 patients altogether with acute Rhinitis. 80 were treated only with Xylometazoline and 74 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nose operation + Xylometazoline
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients after an operation in the nose and paranasal cavities who were treated only with Xylometazoline. There were 40 patients altogether after an operation in the nose and paranasal cavities. 24 were treated only with Xylometazoline and 16 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nose operation + Xylometazoline + Dexpanthenol
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients after an operation in the nose and paranasal cavities who were treated with Xylometazoline and Dexpanthenol. There were 40 patients altogether after an operation in the nose and paranasal cavities. 24 were treated only with Xylometazoline and 16 were treated with Xylometazoline and Dexpanthenol. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |